J&J Vision touts publication of 2 LipiFlow studies

Johnson & Johnson (NYSE:JNJ) today touted the results from 2 studies of its LipiFlow treatment for meibomian gland dysfunction which causes dry eye disease.

The studies were both published in the journal Clinical Ophthalmology, the company said.

The LipiFlow device is designed to remove blockages from the meibomian gland to allow for proper function, the company said.

“Having a healthy ocular surface is the foundation for visual comfort, and an important factor for success in a variety of eye health treatments, including wearing contact lenses. A key to ocular surface homeostasis is the healthy meibomian gland, as it secretes an oil that prevents evaporation of the eye’s tear film. When the meibomian gland is blocked, the result is often dry eye disease. With millions of patients in need, we wanted to better understand the current treatment options available for patients with contact lens discomfort,” trial investigator Kelly Nichols said in a prepared statement.

The first study examined the effects of a single LipiFlow treatment and reported significantly improved mean meibomian gland function and reduced mean dry eye signs and symptoms at three months for soft contact lens wearers with MGD compared to a control group.

Increased comfortable lens wearing was also reportedly improved by four hours per day, Johnson & Johnson said, with no serious adverse events reported.

In the second study, researchers explored the use of a single 12-minute treatment with Lipiflow. Results indicated that the 12-minute treatment was more effective than three months of doxycycline taken orally, daily, at improving the dry eye symptoms associated with MGD compared to baseline.

“These results add to the growing body of evidence showing that one, 12-minute treatment with LipiFlow can provide effective relief of the meibomian gland dysfunction and dry eye symptoms without serious side effects. We’re proud to offer a proven, first-line option that may help improve eye health for the millions of people living with this chronic condition today,” J&J Vision surgical worldwide prez Tom Frinzi said in a press release.

Last month, Johnson & Johnson beat Wall Street’s expectations with its fourth-quarter results but missed the consensus forecast for the full year.

The post J&J Vision touts publication of 2 LipiFlow studies appeared first on MassDevice.

from MassDevice http://ift.tt/2sb2tz4